BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/8/2017 3:24:00 PM | Browse: 910 | Download: 1186
Publication Name World Journal of Clinical Oncology
Manuscript ID 29493
Country/Territory Italy
Received
2016-08-17 10:44
Peer-Review Started
2016-08-18 18:06
To Make the First Decision
2016-09-26 10:29
Return for Revision
2016-09-28 09:21
Revised
2016-11-09 08:38
Second Decision
2016-11-17 16:45
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2016-11-29 08:52
Articles in Press
2016-11-29 08:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2017-01-17 16:52
Publish the Manuscript Online
2017-02-08 15:32
ISSN 2218-4333 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Review
Article Title From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis
Manuscript Source Invited Manuscript
All Author List Melissa Bersanelli and Sebastiano Buti
Funding Agency and Grant Number
Corresponding Author Sebastiano Buti, MD, PhD, Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126 Parma, Italy. sebabuti@libero.it
Key Words Immune checkpoint inhibitors; PD-1; PD-L1; Checkpoint inhibitors; Cancer treatment; Immune checkpoint blockade; Anti-PD-1 antibodies; Anti-PD-L1 antibodies
Core Tip The onset of PD-1/PD-L1 targeted therapy in oncology has demonstrated the importance of this axis in the immune escape across almost all human cancers. A sort of revolution has been happening with the investigation of the new immune checkpoint inhibitors in the field of anticancer therapy. The aim of this article is to review the most up to date literature about the clinical effectiveness of the antibodies targeting PD-1/PD-L1 axis for the treatment of advanced solid tumors and to explore transversal challenges in the immune checkpoint blockade.
Publish Date 2017-02-08 15:32
Citation Bersanelli M, Buti S. From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin Oncol 2017; 8(1): 37-53
URL http://www.wjgnet.com/2218-4333/full/v8/i1/37.htm
DOI http://dx.doi.org/10.5306/wjco.v8.i1.37
Full Article (PDF) WJCO-8-37.pdf
Full Article (Word) WJCO-8-37.doc
Manuscript File 29493-Review.doc
Answering Reviewers 29493-Answering reviewers.pdf
Audio Core Tip 29493-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 29493-Conflict-of-interest statement.pdf
Copyright License Agreement 29493-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 29493-Language certificate.pdf
Peer-review Report 29493-Peer-review(s).pdf
Scientific Misconduct Check 29493-Scientific misconduct check.pdf
Scientific Editor Work List 29493-Scientific editor work list.pdf